Spiritual Care for Leukemia

CT
Overseen ByClinical Trials Intake
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Chicago
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine if spiritual care sessions can be integrated into the treatment plan for patients hospitalized with leukemia. Participants will be randomly assigned to receive either standard care or special guided spiritual sessions (SCORE Intervention). The trial seeks adults diagnosed with acute leukemia (AML or ALL) who are currently receiving initial inpatient treatment and can read and understand English. As an unphased trial, this study provides a unique opportunity to explore the potential benefits of spiritual care in enhancing overall well-being during treatment.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It focuses on spiritual care sessions for leukemia patients.

What prior data suggests that the SCORE Intervention is safe for leukemia patients?

Research has shown that spiritual care sessions, such as the SCORE Intervention, are generally safe and well-received by patients. This trial aims to integrate spiritual care into leukemia treatment. Spiritual care does not involve drugs or physical treatments, so it lacks the physical side effects associated with medications or surgeries. Instead, it offers emotional and spiritual support, which is typically safe for participants.

Considering participation in a trial like this can be reassuring, as spiritual care focuses on enhancing mental and emotional well-being. Many participants find these sessions beneficial in managing their illness. Studies have not indicated any harm from these interventions. It is always advisable to discuss any concerns with a healthcare provider before joining the trial.12345

Why are researchers excited about this trial?

Researchers are excited about the SCORE Intervention for leukemia because it focuses on spiritual care, an aspect that's often overlooked in traditional treatments. While standard leukemia treatments like chemotherapy, radiation, and targeted therapies directly attack cancer cells, SCORE aims to enhance patients' overall well-being and resilience by addressing their spiritual needs. This approach is innovative because it seeks to complement existing medical treatments, potentially improving quality of life and emotional health during the challenging journey of cancer treatment.

What evidence suggests that the SCORE Intervention is effective for leukemia?

Research suggests that spiritual care might improve the well-being of patients with leukemia. Although direct evidence does not show that spiritual care leads to better leukemia outcomes, studies have indicated that holistic approaches, including emotional and spiritual support, can enhance the quality of life for those with serious illnesses. This trial includes a Spiritual Intervention Arm, where participants receive a study-specific spiritual care intervention, and a No Intervention Arm for comparison. This support may help patients manage stress and improve mental health during treatment. The specific spiritual care tested in this trial is unique, so its effects will be directly measured. Overall, adding spiritual care to treatment plans is seen as a way to potentially enhance patients' well-being during medical treatment.26789

Who Is on the Research Team?

WS

Wendy Stock

Principal Investigator

University of Chicago

Are You a Good Fit for This Trial?

This trial is for English-speaking adults aged 18 or older who have been diagnosed with Acute Leukemia (AML or ALL) and are currently receiving inpatient initial therapy. Participants must be able to understand and sign a consent form.

Inclusion Criteria

I am 18 years old or older.
I can understand and am willing to sign the consent form.
I am diagnosed with acute leukemia and am receiving my first treatment in the hospital.
See 1 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either standard inpatient spiritual care or study-specific guided spiritual sessions

Approximately 2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • SCORE Intervention

Trial Overview

The study aims to see if spiritual care sessions can be effectively added to the treatment plan for leukemia patients. It compares standard spiritual care provided during hospitalization with additional guided spiritual sessions tailored for the study.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Active Control

Group I: Spiritual Intervention ArmExperimental Treatment1 Intervention
Group II: No Intervention ArmActive Control1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Chicago

Lead Sponsor

Trials
1,086
Recruited
844,000+

Citations

Effectiveness of Three Prognostic Scoring Systems in ... - PMC

Conclusion: None of the scoring systems predicted the response and outcome effectively in children with CML CP on front line Imatinib.

UF-developed genetic score improves outcomes by ...

It can improve outcomes by about 30% in individual patients matched to a more intense chemotherapy regimen, according to the study, published ...

Prognostic scoring systems in chronic myeloid leukaemia

Prognostic scores are an important tool in medical statistics. In chronic myeloid leukaemia (CML), prognostic models have existed for many ...

Pharmacogenomic Score Effectively Personalizes Treatment ...

Our findings suggest that tailoring induction regimens using ACS10 scores can significantly improve outcomes in patients with AML. Given the ...

Outcomes with intensive treatment for acute myeloid ...

Concordant with published studies,2,13,31 our data show that OS in intensively treated AML patients improved over four consecutive calendar ...

Chronic myeloid leukemia outcomes according to baseline ...

Twenty‐two CML‐related deaths (16.5%) occurred mostly in the first 2 years from diagnosis, higher in 2G‐TKIs patients (sHR, 1.75; 95% CI, 0.52– ...

Research Snapshot: Genetic score shows promise in ...

A genetic score holds promise for improving treatment results in patients with acute myeloid leukemia (AML) who have traditionally had poor outcomes.

Pilot study: Assessing allostatic load score and outcomes in ...

Conclusion: The preliminary findings from this pilot study suggest a relationship between high AL score and mortality in AML patients.

Updated efficacy and safety data from the AGILE study in ...

Long-term follow-up data (June 2022) for OS, blood count recovery, transfusion independence and safety are described here. Results: 148 pts were ...